Research work · 2002

The Safety of Voriconazole

Brian A. Potoski, Jack E Brown

Clinical Infectious Diseases

Abstract

Sir—We read with interest the article by Denning et al. entitled “Efficacy and Safety of Voriconazole in the Treatment of Acute Invasive Aspergillosis” [1]. In their study, Denning and colleagues reported adverse events that indicate an area of concern. Specifically, 20 patients (14.6%) developed abnormal liver function values (>3 or 5 times the upper limit of normal). As a result, therapy was discontinued for these patients, in accordance with the study protocol. The authors indicated that 11 of these 20 patients had received hematopoietic stem cell transplants and that only 5 of the 11 patients had abnormal laboratory values that were attributed to another disease process. The authors also reported that some patients had elevated transaminase levels, some had elevated alkaline phosphatase levels, and some had both. In addition, the authors stated that 6 of the 22 patients with plasma concentrations of voriconazole of >6000 ng/mL developed abnormal liver function or liver failure. In the largest study of voriconazole to date, Walsh et al. [2] concluded that voriconazole use was not associated with any increase in the frequency of hepatic abnormalities, as compared with use of liposomal amphotericin B. Walsh et al. [2] also stated that the low rates of hepatotoxicity they noted may not pertain to patients who are receiving prolonged treatment for proven infection. In an effort to compare adverse events, with emphasis on hepatic laboratory abnormalities reported in clinical trials of voriconazole in immunocompromised patients, we compiled a table for review (table 1). Hepatic laboratory abnormalities reported in clinical trials of voriconazole in immunocompromised patients. The US Food and Drug Administration (FDA) Antiviral Drugs Advisory Committee's briefing document for voriconazole adds insight on this subject [8]. It is the opinion of the committee that, according to an overall review of the data, the incidence of hepatic function test abnormalities among voriconazole-treated patients is greater than the incidence among healthy volunteers who receive placebo, greater than the incidence among fluconazole-treated patients with esophageal candidiasis, and similar to the incidence among patients who received lipid formulations of amphotericin B as empirical therapy or amphotericin B plus another licensed antifungal agent as treatment for acute invasive aspergillosis. Furthermore, a literature comparison led the committee to conclude that, in equivalent, severely ill populations, the risk of hepatotoxic reactions associated with voriconazole use is not greater than that associated with other antifungal therapies [8]. However, there may be considerable challenges associated with voriconazole therapy. Voriconazole exhibits nonlinear pharmacokinetics [6], and some clinical trials have reported a wide range of serum concentrations of the drug. In addition, voriconazole is extensively metabolized in the liver, mainly by the CYP2C9, CYP2C19, and CYP3A4 isoenzymes [9]. Patients who are at risk of acquiring fungal infections are typically receiving multiple medications, and voriconazole could potentially interact with drugs that act as either substrates, inhibitors, or inducers of these isoenzymes. Drugs that are substrates for these hepatic enzymes include—but are not limited to—diazepam, cyclosporine, diltiazem, tacrolimus, verapamil, sulfamethoxazole, and phenytoin [10]. In a study by Romero et al. [3], the effect of voriconazole use on the pharmacokinetics of cyclosporine was evaluated, and it was found that the mean area under the curve of cyclosporine increased 1.7-fold in the presence of voriconazole. Romero and colleagues recommended that cyclosporine doses be halved and that concentrations of cyclosporine in blood be carefully monitored in patients who are concomitantly administered voriconazole. In a look toward potential dosing challenges for younger patients, Walsh et al. [4] reported that the median plasma concentration in children who received voriconazole at a dosage of ⩾4 mg/kg iv b.i.d. (median plasma concentration, 1566 ng/mL) was lower than that in adult volunteers who received voriconazole at dosages of 4 mg/kg b.i.d. and 5 mg/kg b.i.d. (median plasma concentrations, 5671 ng/mL and 7404 ng/mL, respectively), which suggests that the rate of clearance of voriconazole may be greater in children than in adults. Also, although it is not certain, there may be an association between serum concentrations of voriconazole of >6000 ng/mL and abnormal liver function. Denning et al. [1] noted that serum concentrations of voriconazole of >250 ng/mL are consistent with the threshold of response to invasive aspergillosis. We agree with Denning et al. [1] that dose modification guidelines need to be developed. Furthermore, we believe that a validated assay to determine serum concentrations of the drug should be available for clinicians to ensure efficacy and prevent toxicity. Clinicians should recognize that, although voriconazole is an azole antifungal, it may have more potential for hepatotoxicity than do the previously available azole antifungals. In addition, with the availability of this drug in an oral form, caution must be exercised for patients who may receive voriconazole as part of their outpatient regimen, especially for patients who have hepatic insufficiency or who are taking medications that may potentially interact with voriconazole.

DOI: 10.1086/343746